Experimental Mesothelioma Drug That Disables the PRX3 Enzyme Controlled Disease in Two-Thirds of Patients in Small Trial

An experimental drug that disables PRX3 controlled mesothelioma in 67% of patients at 12 weeks in a small Phase 1 trial. It is not FDA-approved.

Have A Referral?